A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
The goal of this phase 1/2 multicenter, open-label, single-arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in pati...
The Efficacy and Safety of Elritercept in Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Anemia (RENEW)
This study (KER-050-D301) is evaluating the efficacy and safety of elritercept (KER-050) versus placebo in adult participants with transfusion-dependent anemia with very low, low, or intermediate risk...
A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
The purpose of this study is to evaluate the effects of KER-050 on anemia in patients with very low, low or intermediate risk MDS....
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed hig...
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)...
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Myeloid malignancies which include AML (acute myeloid leukemia) and MDS (myelodysplatic syndrome) are cancers of the bone marrow which lead to bone marrow failure. The bone marrow is the place or fact...
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participant...
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previ...
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
This phase 2 study aims to confirm the efficacy seen in the prior phase 1 trial, and further contribute to this effort through the collection of leukemia cells pre- and post- in vivo IFN-γ therapy. As...
Top Cities for Myelodysplastic Syndromes Clinical Trials
Myelodysplastic Syndromes clinical trials are recruiting across 51 cities. Here are the cities with the most active studies:
About Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature properly. MDS can progress to acute myeloid leukemia. Treatments include growth factors, chemotherapy, and stem cell transplant.
Clinical trials are advancing new treatments for myelodysplastic syndromes. Currently, 9 studies are recruiting a combined 1,026 participants across the United States. Research is being conducted by 8 organizations including Chordia Therapeutics, Inc., Takeda, Akeso and 5 others.
2026 Myelodysplastic Syndromes Research Landscape
As of March 2026, the myelodysplastic syndromes clinical trial landscape includes 9 actively recruiting studies across 51 cities in the United States. These studies are collectively seeking 1,026 participants, with an average enrollment target of 114 per study.
Research is being led by 8 different organizations, including Chordia Therapeutics, Inc., Takeda, Akeso, Rigel Pharmaceuticals, Montefiore Medical Center, and 3 others.
Geographically, myelodysplastic syndromes trials are most concentrated in Houston, Texas (4 trials); Los Angeles, California (3 trials); Jacksonville, Florida (2 trials); Seattle, Washington (2 trials); Duarte, California (2 trials) and 7 other cities.
Featured Myelodysplastic Syndromes Studies
Highlighted recruiting studies for myelodysplastic syndromes, selected by enrollment size and research scope.
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
The goal of this phase 1/2 multicenter, open-label, single-arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS), or MDS/MPN (including CMML). The phase 1 part of the study consists of sequential ...
The Efficacy and Safety of Elritercept in Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) With Anemia (RENEW)
This study (KER-050-D301) is evaluating the efficacy and safety of elritercept (KER-050) versus placebo in adult participants with transfusion-dependent anemia with very low, low, or intermediate risk MDS, or more recently defined as myelodysplastic neoplasms, with or without ring sideroblasts. The study is divided into the Screening Period, Double-blind Treatment Period, Safety Follow-Up Period a...
A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
The purpose of this study is to evaluate the effects of KER-050 on anemia in patients with very low, low or intermediate risk MDS.
Frequently Asked Questions About Myelodysplastic Syndromes Clinical Trials
Are there myelodysplastic syndromes clinical trials near me?
Yes, there are 9 myelodysplastic syndromes clinical trials currently recruiting across 51+ cities in the United States, including Houston, Texas; Los Angeles, California; Jacksonville, Florida. Browse the studies above to find one at a location convenient for you.
How do I join a myelodysplastic syndromes clinical trial?
To join a myelodysplastic syndromes clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are myelodysplastic syndromes clinical trials free?
Yes, participation in myelodysplastic syndromes clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of myelodysplastic syndromes treatments are being studied?
Current myelodysplastic syndromes clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 8 research organizations.
Is it safe to participate in myelodysplastic syndromes clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov